1. Market Research
  2. > Therapy
10 reports for Salicylic Acid (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Bone Anchored Hearing Aids Market 2016-2020

  • $ 2500
  • September 2016
  • 68 pages

It may be a result of complications at birth, chronic ear infections, genetic defects, exposure to excessive noise (industry), and by the long-term use of particular drugs such as aspirin, ibuprofen (non-steroidal anti-inflammatory drug), and aminoglycosides such as gentamicin, etc.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • ENT Medical Device
  • Salicylic Acid
  • World

Global Hearing Aids and Implants Market: Trends, Opportunities and Forecasts

  • $ 2200
  • May 2016
  • 205 pages

While aging is a natural process where the hearing loss is likely to occur, there are other several causes which are also responsible for the loss of hearing: Continuous exposure to loud noise genetic causes Birth complications Medications such as antibiotics and chemotherapy drugs,

  • Ear, Nose, And Throat Medicine
  • HIV AIDS
  • Salicylic Acid
  • World
  • Market Size

Histamine H4 Receptor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 49 pages

Salicylate is often used because it rapidly induces deficits in startle inhibition by gap-detection which are interpreted as tinnitus-related.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • Therapy
  • Sensorion S.A.

Histamine H4 Receptor - Pipeline Review, H1 2020

  • $ 3500
  • March 2020
  • 52 pages

Salicylate is often used because it rapidly induces deficits in startle inhibition by gap-detection which are interpreted as tinnitus-related.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • Therapy
  • Sensorion S.A.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2018

  • $ 3500
  • September 2018
  • 47 pages

Salicylate is often used because it rapidly induces deficits in startle inhibition by gap-detection which are interpreted as tinnitus-related.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Salicylic Acid
  • Therapy
  • Sensorion S.A.

Mucositis Global Clinical Trials Review, H1, 2020

  • $ 2500
  • February 2020
  • 128 pages

Aspirin and Thymol and Combination of Benzydamine and Chlorhexidine in Reducing Mucositis Severity in Nasopharyngeal Cancer Patient Effectiveness of Mouthwashes: Combination of Aspirin and Thymol and Combination of Benzydamine and Chlorhexidine in Reducing Mucositis Severity in Nas

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Hospital
  • Salicylic Acid
  • Therapy

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H1 2018

  • $ 3500
  • March 2018
  • 55 pages

Tinnitus or Hearing Loss Relationship between GPIAS deficits and ABR thresholds after repeated salicylate The gap-prepulse inhibition of acoustic startle (GPIAS) paradigm using salicylate induction is widely used in preclinical settings for the study of tinnitus.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Salicylic Acid
  • Therapy
  • Sensorion S.A.

Oral Cancer Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020
  • 461 pages

aspirin; celecoxib; cilazapril; curcumin; losartan; metformin; omeprazole; propranolol Gillies McIndoe Research Institute ## Apr 2018 ## ## Target Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • Oropharynx Cancer
  • Salicylic Acid

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2018

  • $ 2500
  • June 2018
  • 258 pages

aspirin; clopidogrel bisulfate; pembrolizumab Medical University of South Carolina ## Sep 2017 ## Oct 2017 ## Dec 2020 ## ## ## P##Y Purinoceptor ## (ADP Glucose Receptor or P##Y## Platelet ADP Receptor or SP1999 or P##T(AC) or P##Y(AC) or P##Y(cyc) or P##Y## or P##RY##) Antagonist P##Y Purinoceptor

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • Salicylic Acid
  • Therapy

Head And Neck Carcinoma Global Clinical Trials Review, H2, 2017

  • $ 2500
  • August 2017
  • 767 pages

aspirin; clopidogrel bisulfate; pembrolizumab Medical University of South Carolina ## Sep 2017 ## Dec 2020 ## ## P##Y Purinoceptor ## (ADP Glucose Receptor or P##Y## Platelet ADP Receptor or SP1999 or P##T(AC) or P##Y(AC) or P##Y(cyc) or P##Y## or P##RY##) Antagonist P##Y Purinoceptor ## (ADP Glucos

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Hospital
  • Lung Cancer
  • Salicylic Acid


View report >

Ear, Nose, And Throat Medicine Industry in Australia and Australasia

  • June 2017
  • 98 pages

The Aspirin in Reducing Events in the Elderly trial currently underway is collecting audiometric data from some ##, ## Australians over the age of ## years, but results will not be available until 2018 (Lowthian et al, 2016).

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Salicylic Acid
  • Australasia
  • Australia

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on